CEL-SCI Corporation (CVM)

Over the past six months, CEL-SCI Corp. has experienced several events impacting its stock price. CEL-SCI reported its fiscal year ended September 30, 2025, results in December 2025, and early January 2026, announcing a narrowed net loss of $25.41 million for fiscal 2025. In late December 2025, insider purchases by CEO Geert Kersten, CFO Patricia Prichep, and Chief Scientific Officer Eyal Talor were disclosed. In August 2025, CEL-SCI announced and closed a $10 million public offering of common stock at $9.00 per share. A 1-for-30 reverse stock split became effective in May 2025. In May 2025, CEL-SCI announced a significantly positive outcome from its meeting with the U.S. Food and Drug Administration regarding the path to approval for Multikine. The company raised approximately $5.7 million through an at-the-market stock offering in July 2025 and generated gross proceeds of $5 million from a common stock offering in May 2025 to fund operations and Multikine development.

As a clinical-stage biotechnology company primarily focused on the development and commercialization of its investigational drug Multikine, CEL-SCI Corp. does not currently have significant product revenue, therefore, traditional demand seasonality for products and services is not applicable to CEL-SCI's current business model. There is analysis available regarding the monthly seasonality of CEL-SCI's stock performance, which examines how the stock performs during different months of the year. For a company in the development phase, stock performance can be influenced by factors such as clinical trial milestones, regulatory announcements, financing activities, and broader market sentiment towards the biotechnology sector, rather than seasonal fluctuations in product demand.

CEL-SCI Corp. is a clinical-stage biotechnology company focused on immunotherapy products for cancer, autoimmune, and infectious diseases. Their primary product, Multikine, is an immunotherapeutic agent in Phase III clinical trials for advanced primary head and neck squamous cell carcinoma. CEL-SCI is also developing the Ligand Epitope Antigen Presentation System (LEAPS) technology for therapeutic vaccines and has explored HGP-30 against the AIDS virus.

CEL-SCI Corporation is headquartered in Vienna, Virginia, USA, with operations in or near Baltimore, Maryland. The company is pursuing market expansion outside the U.S., particularly in the Middle East, and is working towards potential regulatory clearance and sales of Multikine in Saudi Arabia. CEL-SCI also trades on the German Stock Exchanges under the symbol LSR.

CEL-SCI's brand reputation has been influenced by its ongoing clinical advancements and regulatory interactions. CEL-SCI has made significant regulatory progress, particularly with Multikine in Saudi Arabia, where an application for Breakthrough Medicine Designation was submitted, and the U.S. Food and Drug Administration (FDA) has also given the company the go-ahead for a 212-patient confirmatory registration study for Multikine. The company has presented compelling Phase 3 target-population data for Multikine at major oncology meetings and in a peer-reviewed article, which supports its scientific credibility. CEL-SCI is recognized for its dedication to rigorous scientific research and development, aiming to address unmet medical needs with innovative therapies.

CEL-SCI Corporation's ownership structure includes institutional, retail, and individual investors. Approximately 3.53% to 10.87% of the company's stock is owned by institutional investors, while insider ownership is around 2.14% to 19%. Retail investors hold a significant portion, estimated at around 91.48%. Major institutional owners and shareholders include Vanguard Group Inc., Commonwealth Equity Services, Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, BlackRock, Inc., MAI Capital Management, Geode Capital Management, Llc, Bank Of America Corp /de/, VEXMX - Vanguard Extended Market Index Fund Investor Shares, State Street Corp, Advisor Group Holdings, Inc., Osaic Holdings Inc., Plotkin Financial Advisors LLC, Calton & Associates Inc., Renaissance Technologies LLC. The CEO, Geert Kersten, is also a significant individual owner.